The Overview

  • Douglas Hanahan and Robert Weinberg published a foundational 2000 paper identifying core capabilities all cancers must acquire. Rather than viewing cancer as thousands of distinct diseases, they focused on universal traits that transform a healthy cell into a dangerous one. This framework acts as a biological biography, illustrating how mutations accumulate over years or decades.

  • Healthy cells operate within a strictly governed community, dividing only upon receiving explicit signals and self-destructing via apoptosis when severely damaged. The body relies on built-in defenses like tissue renewal limits, blood supply constraints, and immune surveillance to suppress abnormal cells. Consequently, turning a normal cell into cancer requires numerous independent biological failures.

  • DNA copying errors, environmental carcinogens, and inherited faulty repair genes accelerate the accumulation of mutations in descendent cells. While not a direct hallmark, genomic instability serves as an enabling characteristic that makes acquiring subsequent cancer traits significantly more likely. For instance, inherited faults in genes like BRCA1 or DNA repair genes associated with Lynch syndrome exemplify this vulnerability.

  • Proto-oncogenes normally regulate cell division, but mutations can lock growth accelerators permanently on, as seen with the KRAS gene in colon and lung cancers. Simultaneously, tumor suppressor genes like RB and p53 act as critical cellular brakes to halt division when DNA is damaged. Cancer typically requires both jammed growth accelerators and disabled tumor suppressors to proliferate uncontrollably.

  • Cancer cells evade programmed cell death by disabling damage sensors or overproducing survival proteins like BCL-2, which complicates treatments such as chemotherapy and radiation that rely on triggering apoptosis. Furthermore, normal cells face a division limit determined by telomere shortening, but most cancers bypass this clock by activating telomerase. This enzymatic rebuilding of chromosome tips grants the malignant cell lineage cellular immortality.

  • Tumors evolve into complex neighborhoods composed of cancer cells mixed with connective-tissue, immune, and blood vessel cells rather than homogenous lumps. Chronic inflammation acts as a key enabling characteristic by hijacking the body's wound-healing responses to supply growth factors and supportive signals. Conditions like chronic inflammatory bowel disease illustrate how prolonged inflammation elevates cancer risks.

  • Growing cell colonies soon face oxygen and nutrient deficits, prompting them to trigger the angiogenic switch by releasing signals like VEGF to sprout new blood vessels. Additionally, cancer cells rewire their metabolism through the Warburg effect to rapidly generate the raw building materials needed for incessant cell division. This metabolic greed allows tumors to light up distinctively on diagnostic PET scans.

  • Tumors evade immune surveillance by deploying surface proteins like PD-L1 that interact with T-cell checkpoints to disarm the body's natural hunter cells. The ultimate and most dangerous hallmark is metastasis, wherein cancer cells break through tissue barriers, survive turbulent journeys through blood or lymphatic vessels, and colonize distant organs. Because secondary spread accounts for most cancer deaths, understanding these specialized capabilities helps guide modern targeted therapies and combination treatments.

Introduction

In January 2000, two cancer biologists published a paper that quietly changed how scientists, and eventually doctors and patients, think about cancer. Douglas Hanahan, then at the University of California, San Francisco, and Robert Weinberg of the Whitehead Institute at MIT gave it a simple title: “The Hallmarks of Cancer.” It went on to become one of the most widely cited papers ever published in the journal Cell.

The timing mattered. By the end of the twentieth century, cancer research was drowning in detail. Scientists had catalogued hundreds of kinds of cancer and were discovering mutated genes faster than anyone could make sense of them. Cancer looked less like one disease than like a thousand different diseases, each with its own confusing rules.

Hanahan and Weinberg stepped back and asked a different question. Instead of asking what goes wrong in each particular cancer, they asked: what does a cell have to be able to do in order to become a dangerous cancer at all? Their answer was surprisingly short. Whatever the organ, and whatever the specific mutations, they argued that every cancer must acquire the same small set of capabilities. The routes differ; the destination is the same.

That idea lends itself to a story. In the pages that follow, we trace the life of a single imaginary cell as it gradually acquires these capabilities, one at a time. Think of it as a biography. Real cancers don’t follow one fixed order, and the process usually unfolds over years or even decades. But following one cell makes the logic of cancer visible, and at each stage we’ll pause to note where modern medicine has learned to step in.

Chapter 1: A Good Citizen

Our cell begins life in the lining of the colon. It is one of tens of trillions of cells in a body that works like a vast, carefully governed community. The colon lining is renewed constantly: cells at the surface are shed and replaced every few days. That means a great deal of cell division, and every division is a small chance for something to go wrong.

Like every cell in the body, ours lives by a set of rules. It divides only when its neighbors send a signal saying more cells are needed. It stops dividing when it receives signals to stop, or when it bumps up against neighbors and the space is full. If it becomes seriously damaged, it quietly self-destructs through a tidy, orderly process called apoptosis, sacrificing itself for the good of the whole. It can divide only a limited number of times over its lineage before it retires. It lives within reach of a blood vessel and takes only its share of oxygen and nutrients. It stays where it belongs. And all the while, the immune system patrols, ready to remove any cell that starts to look abnormal.

These rules are the body’s built-in cancer defenses. To become a cancer, a cell has to break nearly all of them. That is the first, and perhaps most hopeful, lesson of the hallmarks: turning a healthy cell into a dangerous cancer is hard. It requires many independent failures. That is why most of us carry cells with harmful mutations without ever developing cancer, and why cancer becomes more common with age. There has simply been more time for failures to accumulate.

Chapter 2: The First Typo

Every time our cell divides, it must copy its DNA, an instruction manual roughly three billion letters long. Mistakes happen. Most are caught and fixed by teams of repair proteins that proofread the copy. Other damage comes from outside: tobacco smoke, ultraviolet light, alcohol, certain infections, and sometimes nothing more than chance. Some people inherit faulty repair genes from a parent, which gives their cells a head start toward trouble.

Remarkably, researchers who have examined healthy-looking tissue, such as skin and the lining of the esophagus, have found it full of small patches of cells carrying mutations associated with cancer. The vast majority of those patches never become cancer. A mutation is not a diagnosis.

Our cell’s first misfortune is damage to one of its repair genes. On its own, this doesn’t make it a cancer. It doesn’t grow faster or look any different. But from now on, errors accumulate more quickly in its descendants, and the odds of the next misfortune rise. In their 2011 update, Hanahan and Weinberg called this genomic instability an “enabling characteristic.” It is not a hallmark itself; it is the engine that makes acquiring the hallmarks more likely. Inherited faults in genes such as BRCA1 and BRCA2, or in the repair genes involved in Lynch syndrome (an inherited condition that raises colon cancer risk), work this way.

Chapter 3: A Stuck Accelerator

The first true hallmark Hanahan and Weinberg described is the ability to keep sending itself the signal to grow. A normal cell is like a car that moves only when someone outside presses the accelerator. Growth signals arrive from neighboring cells, latch onto receptors on the cell’s surface, and set off a chain of messages inside telling the cell to divide.

Genes that drive this growth machinery are called proto-oncogenes. When one of them is mutated so that it is permanently switched on, it becomes an oncogene, and the accelerator is stuck to the floor. Our cell acquires a mutation in a gene called KRAS, one of the most common oncogenes in colon, pancreatic and lung cancers. The KRAS protein normally acts like a relay switch that flips on briefly when a growth signal arrives and then flips off. The mutated version stays on. Our cell no longer waits for permission to divide.

Other cancers find different ways to jam the same accelerator. In about 15 to 20 percent of breast cancers, cells carry extra copies of a growth receptor called HER2, so they hear a whisper of a growth signal as a shout.

Chapter 4: Cut Brakes

A stuck accelerator alone is usually not enough, because the body also has brakes. Genes called tumor suppressors make proteins that halt cell division when conditions aren’t right: when DNA is damaged, when the neighborhood is crowded, or when growth isn’t needed. One of them, RB, acts as a gatekeeper that decides whether a cell may enter the division cycle at all. Another, p53, is so important that it is often called the “guardian of the genome.” It senses damage and can stop the cell in its tracks or order it to die. Mutations in p53 are found in roughly half of all human cancers.

Brakes are usually harder to break than accelerators are to jam, because each cell carries two copies of most genes, one from each parent. In the early 1970s, the physician-scientist Alfred Knudson studied a childhood eye cancer called retinoblastoma and proposed that both copies of a brake gene must be lost before cancer can develop. People who inherit one faulty copy start life with one strike already against them, which helps explain why some cancers run in families.

In our story, our cell’s descendants lose both copies of a brake gene. (In real colon cancers, loss of a tumor suppressor called APC is often one of the earliest events of all, which is a reminder that the order varies.) Grown in a laboratory dish, normal cells stop dividing when they touch one another and form a neat single layer. Cancer cells keep going, piling up in heaps. Our cell’s family has begun to heap.

Chapter 5: Refusing to Die

By now, our cell’s descendants are dividing with damaged DNA. In a healthy body, this would set off an alarm. Sensors like p53 would detect the damage and trigger apoptosis, the self-destruct program. Apoptosis is not a violent death; the cell dismantles itself neatly and is cleared away without disturbing its neighbors. Every day, billions of cells in your body die this way, and that is a good thing.

Cancer cells learn to ignore the order. Some lose the sensors that detect damage. Others overproduce “survival” proteins that block the self-destruct machinery. One such protein, BCL-2, was first discovered because it was overactive in a type of lymphoma. It doesn’t make cells divide faster; it simply keeps cells alive that should have died.

This hallmark matters doubly for patients. Many chemotherapy drugs and radiation treatments work by damaging cancer cells so badly that they trigger their own self-destruct programs. A cell that has learned to resist death can also resist treatment.

Chapter 6: Beating the Clock

Even a cell that divides freely and refuses to die faces one more limit. In 1961, the biologist Leonard Hayflick showed that normal human cells grown in the laboratory divide only about 40 to 60 times before they stop for good. The reason lies in the tips of our chromosomes, called telomeres. They work something like the plastic caps on the ends of shoelaces, protecting the DNA from fraying. Each time a cell divides, its telomeres get a little shorter. When they become too short, the cell retires or dies.

To grow without limit, a cancer has to beat this clock. Most do it by switching on an enzyme called telomerase, which rebuilds telomeres. Telomerase is normally active mainly in a few cell types, such as certain stem cells, yet it is reactivated in roughly 85 to 90 percent of cancers. The rest use an alternative method to maintain their chromosome tips. Our cell’s lineage finds the switch. Its family is now, in principle, immortal.

The most famous example of cellular immortality comes from a tumor. In 1951, cells were taken, without her knowledge or consent, from a cervical cancer in a young woman named Henrietta Lacks. Her cells, known as HeLa cells, are still dividing in laboratories around the world today and have contributed to countless medical advances, a legacy that has also prompted important conversations about consent and fairness in research.

Chapter 7: Neighbors Turned Accomplices

By now, our cell’s descendants have formed a small growth, a polyp, on the colon wall. It would be easy to imagine this growth as a lump of identical rogue cells. It isn’t. A tumor is more like a neighborhood. Mixed in among the cancer cells are connective-tissue cells, immune cells, and blood vessel cells, and the cancer cells increasingly bend these neighbors to their purposes. Scientists call this the tumor microenvironment.

One of the most important ways this happens is through inflammation. Inflammation is the body’s healing response: when tissue is injured, immune cells rush in and release growth factors, signals that build new blood vessels, and enzymes that remodel tissue. That’s exactly what a wound needs, and exactly what a tumor wants. In 1986, the pathologist Harold Dvorak described tumors as “wounds that do not heal,” a phrase that captures how cancers hijack the repair process.

Long-lasting inflammation also raises cancer risk in the first place. People with ulcerative colitis, a chronic inflammatory bowel disease, have a higher risk of colon cancer. Chronic infection with the stomach bacterium H. pylori raises the risk of stomach cancer, and chronic hepatitis raises the risk of liver cancer. In 2011, Hanahan and Weinberg named tumor-promoting inflammation as a second “enabling characteristic.”

Chapter 8: Building Supply Lines

Our cell’s growing family now faces a supply problem. Cells need oxygen and nutrients, and these can travel only a short distance from a blood vessel. Without its own blood supply, a tumor generally cannot grow much beyond a millimeter or two, about the size of a pinhead.

In 1971, the surgeon and researcher Judah Folkman proposed that tumors overcome this limit by sending out chemical signals that coax nearby blood vessels to sprout new branches toward them, a process called angiogenesis. Many scientists dismissed the idea at first. Folkman persisted, and he turned out to be right. Somewhere along the way, a tumor flips what researchers now call the “angiogenic switch,” releasing signals such as VEGF (vascular endothelial growth factor). Our cell’s colony does exactly this. New vessels snake toward it, and with them comes a steady supply of fuel and a possible escape route.

Chapter 9: Changing the Fuel

In the 1920s, the German biochemist Otto Warburg noticed something odd. Cancer cells consumed enormous amounts of glucose (blood sugar) and broke it down through a fast, seemingly wasteful process, even when plenty of oxygen was available to burn it more efficiently. For decades, the “Warburg effect” was treated as a curiosity.

In their 2011 update, Hanahan and Weinberg promoted rewired metabolism to the status of a full hallmark. Today scientists think cancer cells reorganize their metabolism not mainly to make energy efficiently, but to churn out the raw building materials needed to make new cells quickly. Our cell’s family, dividing relentlessly, has retooled its kitchen for mass production.

Patients encounter this hallmark more often than they might realize. A PET scan works by injecting a slightly radioactive form of glucose. Because many tumors take up glucose so greedily, they light up on the scan.

Chapter 10: Hiding in Plain Sight

All this time, our cell’s family has been at risk of being caught. The immune system’s T cells patrol the body, inspecting other cells for signs that something is wrong. The idea that the immune system routinely destroys budding cancers, called immune surveillance, was proposed in the 1950s and 1960s. It remained controversial for decades, but strong evidence supports it: people whose immune systems are suppressed, such as organ transplant recipients, have higher rates of certain cancers.

Our cell’s descendants survive because they learn to hide or to disarm their hunters. One clever trick exploits the immune system’s own safety catches. T cells carry “checkpoint” proteins that act as brakes, preventing them from attacking healthy tissue. A protein called PD-1 is one of these brakes. Many tumors display a matching protein, PD-L1, on their surface. When a T cell approaches, the tumor presses its brake. The hunter stands down.

Chapter 11: Leaving Home

The final hallmark in the original list is the most dangerous. Up to now, our cell’s family has stayed put. Most cancer deaths result not from the original tumor but from its spread to other parts of the body, a process called metastasis.

To spread, cancer cells must accomplish a remarkable series of feats. They loosen the molecular “glue” that holds them to their neighbors. They break through the thin sheet of tissue that separates the colon lining from the deeper layers. They squeeze into a blood or lymph vessel, survive the turbulent journey through the bloodstream, exit at a distant site, and then adapt to an entirely foreign environment. Each step is hard. The great majority of cancer cells that enter the bloodstream die. But a tumor sheds huge numbers of cells, and only a few need to succeed.

In 1889, the English surgeon Stephen Paget noticed that cancers don’t spread randomly. Breast cancer tends to travel to bone, liver and lung; colon cancer most often to the liver. He compared tumor cells to seeds that can take root only in congenial soil. His “seed and soil” idea still guides research. For colon cancer, part of the explanation is plumbing: blood from the intestines flows first to the liver. A few of our cell’s descendants make that journey and lodge there. Some may sit quietly for years, a state called dormancy, which helps explain why cancer can sometimes return long after treatment seemed successful.

Chapter 12: The Shape-Shifter

If this were the whole story, it would be a tidy one. But Hanahan and Weinberg never claimed their list was final, and the story kept growing. In 2022, Hanahan, now at the Swiss Institute for Experimental Cancer Research in Lausanne, published a further update titled “Hallmarks of Cancer: New Dimensions.” He proposed several new candidates, explicitly offering them as provisional ideas for debate.

The first is phenotypic plasticity, the ability of cancer cells to change their identity. Normal cells mature into fixed roles, like a colon cell that stays a colon cell. Some cancer cells reverse that maturation or switch identity altogether. Certain prostate and lung cancers, for example, can transform into a different type of cancer under the pressure of treatment, slipping out from under the drugs that were working.

The second is nonmutational epigenetic reprogramming. Genes can be switched on and off by chemical tags attached to DNA and its packaging, without any change to the DNA letters themselves. Those tags can be influenced by the cell’s surroundings, which means a cancer’s behavior is shaped not only by its mutations but by its environment.

The third involves the trillions of microbes living in and on us. Research increasingly suggests that the bacteria in our gut can influence cancer risk and even how well some patients respond to immunotherapy. The fourth involves senescent cells, worn-out cells that have stopped dividing but linger, releasing inflammatory signals that can encourage nearby tumors.

In our story, these newer ideas show up as a final twist. Our cell’s descendants are not a fixed enemy. They can change, adapt, and reshape themselves in response to their surroundings and to treatment.

What This Biography Teaches Us

Step back and look at the whole life story of our cell, and a few lessons stand out.

First, becoming cancer is difficult. A cell has to break nearly every rule the body has built to keep it in line, and most cells with harmful mutations never manage it. That is why prevention and early detection work: they interrupt the biography before it reaches its most dangerous chapters.

Second, every capability a cancer acquires is also a dependency. A cancer that relies on a stuck accelerator can be hurt by blocking that accelerator. A cancer that hides behind PD-L1 can be exposed by removing its disguise. This is the deepest practical gift of the hallmarks framework: it turned cancer from a bewildering mass of details into a map of possible weak points. It also explains why doctors increasingly combine treatments, because hitting several hallmarks at once leaves the cancer fewer escape routes.

Third, cancer evolves. A tumor is a population of cells, and like any population under pressure, it changes. When a treatment kills most of the cells, the few that happen to resist can survive and regrow. That is why resistance develops, and why ongoing monitoring and second-line treatments matter.

Fourth, the map is still being drawn. The authors themselves revised their framework twice in twenty-two years, adding new hallmarks and enabling characteristics each time. Other scientists have offered thoughtful criticism. In 2010, the biologist Yuri Lazebnik pointed out that most of the original hallmarks are also found in benign, non-spreading tumors, and that only invasion and metastasis truly separate a malignant cancer from a harmless growth. Others note that the framework describes what cancers do more than it explains why. These debates don’t diminish the hallmarks; they show the framework working as good science should, as a useful lens that keeps being tested and improved rather than a finished truth.

It is also worth noticing how many of the ideas in this story began as observations that didn’t fit the accepted view of their time: Warburg’s sugar-hungry cells, Folkman’s starving tumors, Paget’s seeds and soil, the early, doubted case for immune surveillance. Careful attention to what is actually happening, in the laboratory and in patients, has repeatedly pushed the science forward.

Questions Worth Asking Your Care Team

If you or someone you love is facing cancer, the hallmarks can help you have more informed conversations. A few questions to consider:

  • What features of my cancer is my treatment designed to target, and how does it work?

  • Has my tumor been tested for specific genetic changes or markers, such as HER2, KRAS, or PD-L1, that might open the door to targeted therapy or immunotherapy?

  • Is there a possible inherited component to my cancer, and should I or my family members consider genetic testing?

  • If this treatment stops working, what does resistance usually look like, and what options would come next?

  • Are there clinical trials exploring newer approaches for my type of cancer?

A Closing Thought

Our imaginary cell began as a good citizen and, through a long chain of misfortunes, became something formidable. But the very length of that chain is the hopeful part. A cancer has to accomplish many things, all at once, and keep accomplishing them. Every one of those requirements is a place where the story can be interrupted, whether by a screening test, a lifestyle change that lowers risk, a targeted drug, or an immune system freed to do its job. The biography of cancer is still being written, by researchers, clinicians and patients alike, and its later chapters are being written with more understanding than ever before.